Sebi orders forensic audit of Sun Pharma financial statements from FY16-18

Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic audit

Sun Pharma
Sun Pharma
Press Trust of India New Delhi
1 min read Last Updated : Sep 05 2019 | 9:25 PM IST

Drug major Sun Pharmaceutical Industries on Thursday said a forensic audit has been ordered by markets regulator Sebi with regard to its financial statements for three financial years between 2015-16 and 2017-18.

In a regulatory filing, Sun Pharma said, "A forensic audit has been ordered by Sebi w.r.t. the financial statements of Sun Pharmaceutical Industries Ltd for the financial years ending March 31, 2016, March 31, 2017 and March 31, 2018".

The said forensic audit is currently going on, it added.

Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic audit.

A forensic audit is an examination and evaluation of a firm's or individual's financial records to derive evidence that can be used in a court of law or legal proceeding.

Shares of Sun Pharmaceutical Industries closed at Rs 431.95 per scrip on the BSE, up 1.30 per cent from its previous close.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Sun PharmaSebi

First Published: Sep 05 2019 | 8:55 PM IST

Next Story